Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 4/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.31 |
| ▸ | THRB | P10828 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22614077 | 1.00 | ATF4 (0.37) | ATF4TRPV1MAPTTHRBSMN1; SMN2 | |
| SCHEMBL29409091 | 1.00 | ATF4 (0.37) | ATF4TRPV1MAPTTHRBSMN1; SMN2 | |
| SCHEMBL29409120 | 1.00 | ATF4 (0.37) | ATF4TRPV1MAPTTHRBSMN1; SMN2 | |
| SCHEMBL29409027 | 0.91 | ATF4 (0.38) | ATF4MAPTTHRBSMN1; SMN2TP53 | |
| SCHEMBL22614188 | 0.91 | ATF4 (0.38) | ATF4MAPTTHRBSMN1; SMN2TP53 | |
| SCHEMBL29408906 | 0.91 | ATF4 (0.38) | ATF4MAPTTHRBSMN1; SMN2TP53 | |
| SCHEMBL22614117 | 0.91 | ATF4 (0.38) | ATF4MAPTTHRBSMN1; SMN2TP53 | |
| SCHEMBL22614540 | 0.86 | ATF4 (0.37) | ATF4TRPV1 | |
| SCHEMBL22614483 | 0.86 | ATF4 (0.37) | ATF4TRPV1 | |
| SCHEMBL29409177 | 0.86 | ATF4 (0.37) | ATF4TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4237413-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022094244-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2022-05-05 | — | — | WO | disclosed |
| EP-3962906-A1 | SUBSTITUTED CYCLOALKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2022-03-09 | — | — | EP | disclosed |
| US-20200347043-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-05 | — | — | US | disclosed |
| US-20200347043-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-05 | — | — | US | disclosed |
| WO-2020223538-A1 | SUBSTITUTED CYCLOALKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2020-11-05 | — | — | WO | disclosed |
| WO-2020223538-A1 | SUBSTITUTED CYCLOALKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2020-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347043-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ATF4 1/4885TRPV1 2489/4885MAPT 3370/4885 |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ATF4 1/4885TRPV1 2905/4885MAPT 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.